The AirSense 11 device offers both automatic and continuous positive airway pressure, as well as female-specific settings, to treat obstructive sleep apnea. The system also offers regular wireless ...

I initiate coverage of ResMed with a Hold rating, citing dominant OSA positioning but near-term competitive headwinds. RMD’s recurring revenue model leverages device sales, consumables, and SaaS, with ...

For the third quarter of its 2023 fiscal calendar, ResMed broke its recent revenue record, reporting $1.12 billion in global sales. (ResMed) As the global supply chain has begun to slowly untangle ...

SAN DIEGO--(BUSINESS WIRE)--Remote patient monitoring and resupply programs have been shown to improve patient adherence to positive airway pressure (PAP) therapy, according to two separate studies ...

ResMed's management isn't just brushing off the threat of weight loss drugs — it's doubling down on the theory that they'll benefit the company's sleep apnea business. 'We believe that the growth in ...

ResMed (NYSE:RMD), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst ...